Literature DB >> 12464450

The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression.

Mark E Bardgett1, William M Humphrey, John G Csernansky.   

Abstract

Previous studies have shown that excitotoxic hippocampal lesions in rats attenuate the ability of different doses of haloperidol, but not of clozapine, to suppress locomotor activity. The purpose of the present study was to determine if kainic acid-induced hippocampal damage reduces the degree of locomotor suppression produced by two relatively newer antipsychotic drugs, risperidone and olanzapine. Young adult male rats received bilateral intracerebroventricular infusions of the excitotoxin, kainic acid (KA), or vehicle and were tested for locomotor responses to drug treatment 30 days later. Infusions of KA produced neuronal loss in the CA3 region of the dorsal hippocampus in every rat. As reported previously, KA lesions reduced the ability of haloperidol (0.35 mg/kg) to completely suppress the locomotor activity elicited by amphetamine (1.5 mg/kg) relative to the effect of haloperidol in non-lesioned controls. Lesioned animals treated with a moderate dose of risperidone (1.4 mg/kg) also exhibited significantly more locomotor activity after amphetamine treatment in comparison to control animals. A trend toward greater activity was also observed in the lesioned group relative to the control group after olanzapine (3.0 mg/kg) injection (p =.09, 2-tailed). The locomotor effects of lower and higher doses of risperidone and olanzapine were not altered by kainic acid lesions. These data suggest that the locomotor-suppressive effects of moderate doses of risperidone and, perhaps, olanzapine involve hippocampal neurons, but that higher doses of each drug can suppress activity in a hippocampal-independent manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464450     DOI: 10.1016/S0893-133X(02)00376-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  6 in total

1.  Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Authors:  Mikhail Kalinichev; Claire Rourke; Alex J Daniels; Mary K Grizzle; Christy S Britt; Diane M Ignar; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

2.  An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Authors:  Danuta Marona-Lewicka; Charles D Nichols; David E Nichols
Journal:  Neuropharmacology       Date:  2011-02-23       Impact factor: 5.250

3.  Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.

Authors:  Matthew A Gannon; Clifford J Brown; Rachel M Stevens; Molly S Griffith; Cecile A Marczinski; Mark E Bardgett
Journal:  Pharmacol Biochem Behav       Date:  2015-01-17       Impact factor: 3.533

4.  The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum.

Authors:  Melkaye G Melka; Benjamin I Laufer; Patrick McDonald; Christina A Castellani; Nagalingam Rajakumar; Richard O'Reilly; Shiva M Singh
Journal:  Clin Epigenetics       Date:  2014-01-02       Impact factor: 6.551

5.  Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis.

Authors:  Melkaye G Melka; Christina A Castellani; Benjamin I Laufer; Raj N Rajakumar; Richard O'Reilly; Shiva M Singh
Journal:  J Mol Psychiatry       Date:  2013-11-04

6.  Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis.

Authors:  Melkaye G Melka; Christina A Castellani; Nagalingam Rajakumar; Richard O'Reilly; Shiva M Singh
Journal:  BMC Neurosci       Date:  2014-09-29       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.